This is particularly relevant in cancer, in which upregulated NO production, due to the induction of the inducible form of nitric oxide synthase (NOS2), is associated with altered tumor gene expression, poor patient outcomes, increased mortality, and resistance to chemotherapy across cancer types1, including triple-negative breast (TNBC)2–12, lung13–15, prostate16,17, brain18, colon19,20, melanoma21–23, and liver24,25. The gene discussed is NOS2; the disease is cancer.